{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T09:10:42Z","timestamp":1782983442874,"version":"3.54.5"},"reference-count":47,"publisher":"European Respiratory Society (ERS)","issue":"3","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/publications.ersnet.org\/user-licence"}],"funder":[{"name":"SanofiGenzyme"},{"DOI":"10.13039\/100006259","name":"Teva","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"GSK"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2025,10,24]]},"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>For a decade, anti-interleukin-5\/receptor \u03b1 (IL5\/R\u03b1) has been available to treat severe asthma, with marked reductions in exacerbation rates and maintenance oral corticosteroid burden. However, little is known about long-term, real-world sustained remission. We aimed to assess the stability of response to anti-IL5\/R\u03b1 over 5\u2005years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      All Danish adults initiating anti-IL5\/R\u03b1 for severe asthma during January 2016 through June 2020 were included. Five-domain remission (no exacerbations, no maintenance oral corticosteroid, forced expiratory volume in 1\u2005s (FEV\n                      <jats:sub>1<\/jats:sub>\n                      ) &gt;80% predicted, Asthma Control Questionnaire score &lt;1.5 and no switch to non-anti-IL5\/R\u03b1) was assessed annually for 5\u2005years.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 482 patients were included (median age 56 years, 48% female). At baseline, 13.9% fulfilled the criteria of no exacerbations, 66.0% of no maintenance oral corticosteroid, 29.7% of FEV\n                      <jats:sub>1<\/jats:sub>\n                      &gt;80% predicted and 26.5% of Asthma Control Questionnaire score &lt;1.5. At year 5, 18.7% had switched to a non-anti-IL5\/R\u03b1 biologic.\n                    <\/jats:p>\n                    <jats:p>The overall remission rate was 17.6\u201323.1% over 5 years. However, remission was found to be dynamic; approximately 15.2% of patients in remission per annum did not fulfil the remission criteria the subsequent year. At least 1\u2005year of remission was achieved by 37.4% of patients, with some patients first achieving remission during year 2 or 3.<\/jats:p>\n                    <jats:p>\n                      Only 7.7% achieved sustained 5-year remission. Failure to achieve remission was driven by permanently impaired FEV\n                      <jats:sub>1<\/jats:sub>\n                      and persistent uncontrolled symptoms. 5-year sustained freedom from exacerbations and maintenance oral corticosteroid use was seen in 33.6% of patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients with severe asthma respond well to anti-IL5\/R\u03b1, with substantial improvements across all domains over 5 years. Remission is a dynamic state with intermittent relapses, and sustained long-term remission is rare using current domains.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/13993003.00926-2025","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T17:10:19Z","timestamp":1764263419000},"page":"2500926","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Long-term efficacy but rare sustained remission: individual-level 5-year stability in anti-IL5\/R\u03b1 biologic therapy response for severe asthma"],"prefix":"10.1183","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5804-0740","authenticated-orcid":false,"given":"Kjell Erik Julius","family":"H\u00e5kansson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9550-6703","authenticated-orcid":false,"given":"Susanne","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4954-0863","authenticated-orcid":false,"given":"Marianne Baastrup","family":"Soendergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3268-785X","authenticated-orcid":false,"given":"Anna","family":"von B\u00fclow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3075-3463","authenticated-orcid":false,"given":"Ole","family":"Hilberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Bonnesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus Rikard","family":"Johnsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie","family":"Lock-Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lycely","family":"Dongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Bisgaard","family":"Borup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Vijdea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda Makowska","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes Martin","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8689-3695","authenticated-orcid":false,"given":"Charlotte Suppli","family":"Ulrik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste","family":"Porsbjerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Sofie","family":"Bjerrum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"2026031201201109000_67.3.2500926.1","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2019.01514"},{"key":"2026031201201109000_67.3.2500926.2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00201813"},{"key":"2026031201201109000_67.3.2500926.3","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jaip.2023.11.007","article-title":"Efficacy and safety of biologics for oral corticosteroid\u2013dependent asthma: a systematic review and network meta-analysis","volume":"12","author":"Phinyo","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026031201201109000_67.3.2500926.4","doi-asserted-by":"publisher","DOI":"10.1111\/cea.12853"},{"key":"2026031201201109000_67.3.2500926.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2023.10.046"},{"key":"2026031201201109000_67.3.2500926.6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S2213-2600(24)00293-5","article-title":"Clinical remission attainment, definitions, and correlates among patients with severe asthma treated with biologics: a systematic review and meta-analysis","volume":"13","author":"Shackleford","year":"2025","journal-title":"Lancet Respir Med"},{"key":"2026031201201109000_67.3.2500926.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.12.006"},{"key":"2026031201201109000_67.3.2500926.8","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1016\/j.jaip.2021.06.041","article-title":"defining a severe asthma super-responder: findings from a Delphi process","volume":"9","author":"Upham","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026031201201109000_67.3.2500926.9","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202405-0894ED"},{"key":"2026031201201109000_67.3.2500926.10","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.2147\/JAA.S391807","article-title":"Long-term efficacy and clinical remission after benralizumab treatment in patients with severe eosinophilic asthma: a retrospective study","volume":"15","author":"Numata","year":"2022","journal-title":"J Asthma Allergy"},{"key":"2026031201201109000_67.3.2500926.11","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12931-023-02439-w","article-title":"Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study","volume":"24","author":"Vultaggio","year":"2023","journal-title":"Respir Res"},{"key":"2026031201201109000_67.3.2500926.12","doi-asserted-by":"crossref","first-page":"1449220","DOI":"10.3389\/fphar.2024.1449220","article-title":"Long-term effects of mepolizumab in patients with severe eosinophilic asthma: a 6-year real-life experience","volume":"15","author":"Stanziola","year":"2024","journal-title":"Front Pharmacol"},{"key":"2026031201201109000_67.3.2500926.13","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01313-2021"},{"key":"2026031201201109000_67.3.2500926.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.09.033"},{"key":"2026031201201109000_67.3.2500926.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2019.07.007"},{"key":"2026031201201109000_67.3.2500926.16","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1016\/j.jaip.2023.08.010","article-title":"Long-term efficacy and safety among patients with severe eosinophilic asthma treated with mepolizumab and its effect on small airways","volume":"11","author":"Strauss","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026031201201109000_67.3.2500926.17","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s40265-021-01597-9","article-title":"REal worlD Effectiveness and Safety of mepolizumab in a multicentric Spanish cohort of asthma patients stratified by eosinophils: the REDES study","volume":"81","author":"Domingo Ribas","year":"2021","journal-title":"Drugs"},{"key":"2026031201201109000_67.3.2500926.18","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1016\/j.jaip.2023.05.025","article-title":"Long-term real-world outcomes of mepolizumab and benralizumab among biologic-naive patients with severe eosinophilic asthma: experience of 3 years\u2019 therapy","volume":"11","author":"Fyles","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026031201201109000_67.3.2500926.19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.arbres.2023.11.011","article-title":"Comparison of long-term response and remission to omalizumab and anti-IL-5\/IL-5R using different criteria in a real-life cohort of severe asthma patients","volume":"60","author":"Valverde-Monge","year":"2024","journal-title":"Arch Bronconeumol"},{"key":"2026031201201109000_67.3.2500926.20","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1016\/j.jaip.2024.08.033","article-title":"Long-term clinical and sustained REMIssion in severe eosinophilic asthma treated with Mepolizumab: the REMI-M study","volume":"12","author":"Crimi","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026031201201109000_67.3.2500926.21","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/resp.14767","article-title":"Sustained remission induced by 2\u2005years of treatment with benralizumab in patients with severe eosinophilic asthma and nasal polyposis","volume":"29","author":"Pelaia","year":"2024","journal-title":"Respirology"},{"key":"2026031201201109000_67.3.2500926.22","doi-asserted-by":"crossref","first-page":"1842117","DOI":"10.1080\/20018525.2020.1842117","article-title":"The Danish Severe Asthma Register: an electronic platform for severe asthma management and research","volume":"8","author":"Hansen","year":"2021","journal-title":"Eur Clin Respir J"},{"key":"2026031201201109000_67.3.2500926.23","unstructured":"Porsbjerg C , von B\u00fclow A , Wimmer A , et al. Dansk Lungemedicinsk Selskab - Retningslinje for Behandling af Sv\u00e6r Astma med Biologiske L\u00e6gemidler [Danish Respiratory Society \u2013 Treatment of Severe Asthma with Biological Drugs]. 2020. https:\/\/lungemedicin.dk\/astma-svaer-biologiske-behandlinger\/ Date last accessed: 31 March 2024."},{"key":"2026031201201109000_67.3.2500926.24","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00202013"},{"key":"2026031201201109000_67.3.2500926.25","unstructured":"Medicinr\u00e5det . Medicinr\u00e5dets Laegemiddelrekommandation og Behandlingsvejledning Vedr\u00f8rende Biologiske Laegemidler til Svaer Astma [Danish Medicines Council's Recommendations and Treatment Guidelines Regarding Biological Therapies for Severe Asthma], version 2.5. 2024. https:\/\/filer.medicinraadet.dk\/media\/z5ena50t\/medicinradets-laegemiddelrek-og-beh-vejl-vedr-svaer-astma-vers-2-5.pdf Date last accessed: 15 July 2024."},{"key":"2026031201201109000_67.3.2500926.26","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1159\/000520725","article-title":"Mepolizumab is an effective option in severe eosinophilic asthma regardless of baseline features: single-center real-life data","volume":"183","author":"\u00d6zt\u00fcrk B","year":"2022","journal-title":"Int Arch Allergy Immunol"},{"key":"2026031201201109000_67.3.2500926.27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403290"},{"key":"2026031201201109000_67.3.2500926.28","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.anai.2023.12.023","article-title":"Impact of pre-biologic impairment on meeting domain-specific biologic responder definitions in patients with severe asthma","volume":"132","author":"Perez-de-Llano","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2026031201201109000_67.3.2500926.29","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2022-001341"},{"key":"2026031201201109000_67.3.2500926.30","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.jaip.2020.10.010","article-title":"Long-term therapy response to anti-IL-5 biologics in severe asthma\u2014a real-life evaluation","volume":"9","author":"Eger","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026031201201109000_67.3.2500926.31","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01497-2024"},{"key":"2026031201201109000_67.3.2500926.32","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1111\/all.16178","article-title":"Real-world biologics response and super-response in the International Severe Asthma Registry cohort","volume":"79","author":"Denton","year":"2024","journal-title":"Allergy"},{"key":"2026031201201109000_67.3.2500926.33","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.jaip.2025.01.023","article-title":"Use of high-dose inhaled corticosteroids and risk of corticosteroid related adverse events in asthma \u2013 findings from the NORDSTAR cohort","volume":"13","author":"von B\u00fclow","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026031201201109000_67.3.2500926.34","doi-asserted-by":"crossref","first-page":"107528","DOI":"10.1016\/j.rmed.2024.107528","article-title":"Comparison of clinical remission criteria for severe asthma patients receiving biologic therapy","volume":"222","author":"Breslavsky","year":"2024","journal-title":"Respir Med"},{"key":"2026031201201109000_67.3.2500926.35","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1016\/j.jaip.2023.05.047","article-title":"Response to biologics and clinical remission in the adult German Asthma Net severe asthma registry cohort","volume":"11","author":"Milger","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026031201201109000_67.3.2500926.36","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.jaip.2020.11.013","article-title":"Remission and changes in severity over 30 years in an adult asthma cohort","volume":"9","author":"Tupper","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026031201201109000_67.3.2500926.37","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1016\/j.jaip.2021.07.058","article-title":"Integrated safety and efficacy among patients receiving benralizumab for up to 5 years","volume":"9","author":"Korn","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026031201201109000_67.3.2500926.38","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1016\/j.jaip.2024.05.016","article-title":"Exploring definitions and predictors of response to biologics for severe asthma","volume":"12","author":"Scelo","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026031201201109000_67.3.2500926.39","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00238-2022"},{"key":"2026031201201109000_67.3.2500926.40","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/cea.13809","article-title":"Switching between biologics in severe asthma patients. When the first choice is not proven to be the best","volume":"51","author":"Papaioannou","year":"2021","journal-title":"Clin Exp Allergy"},{"key":"2026031201201109000_67.3.2500926.41","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jaci.2024.05.023","article-title":"Anti-IL-4R versus anti-IL-5\/5R after anti-IL-5\/5R failure in asthma: an emulated target trial","volume":"154","author":"Valery","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"2026031201201109000_67.3.2500926.42","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.congress-2023.PA4100"},{"key":"2026031201201109000_67.3.2500926.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2023.08.609"},{"key":"2026031201201109000_67.3.2500926.44","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jaip.2023.01.008","article-title":"Toward a predict and prevent approach in obstructive airway diseases","volume":"11","author":"Couillard","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026031201201109000_67.3.2500926.45","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/S2213-2600(25)00299-1","article-title":"Reframing remission in severe asthma: a conceptual framework for distinguishing disease activity versus damage","volume":"13","author":"Porsbjerg","year":"2025","journal-title":"Lancet Respir Med"},{"key":"2026031201201109000_67.3.2500926.46","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2147\/JAA.S438981","article-title":"Sustained effectiveness of benralizumab in na\u00efve and biologics-experienced severe eosinophilic asthma patients: results from the ANANKE study","volume":"17","author":"Cameli","year":"2024","journal-title":"J Asthma Allergy"},{"key":"2026031201201109000_67.3.2500926.47","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00741-2021"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.00926-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T08:20:25Z","timestamp":1773303625000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.00926-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":47,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,12]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1183\/13993003.00926-2025"],"URL":"https:\/\/doi.org\/10.1183\/13993003.00926-2025","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]}}}